| |
|
|
|
Xtalks, Online
2024-06-17
ICON’s experience with the TSO500 solid and liquid biopsy assay
As next-generation sequencing (NGS) becomes a ubiquitous part of routine cancer care, its impact in designing and refining drug development remains in flux. Clinical trial design, biomarker identification and cohort analysis have begun to adapt to the changing landscape over the past decade; however, there are challenges with standardization and federation of data.
In this webinar, the speakers will explore the only kitted comprehensive genomic profiling (CGP) assay submitted to the US Food and Drug Administration (FDA) for pre-market approval (PMA) up to this point, TruSight Oncology 500 (TSO500). Available as a research-use-only tool, TSO500 sets the standard for reproducibility across sites, with exceptional accuracy and specificity across a broad range of preserved tissue types.
The expert speakers will also provide an overview of CGP and cover the validation of TSO500 tissue and present preliminary data on circulating tumor DNA (ctDNA). Moreover, the session will explore the application of NGS in oncology clinical trial biomarker studies, demonstrating its pivotal role in advancing personalized medicine in cancer treatment.
Register for this webinar today to gain insights on using NGS in biomarker studies and the impact of comprehensive genomic profiling on advancing personalized cancer treatment.
Keywords: Precision Medicine, Next Generation Sequencing, Oncology, Biomarkers, Genomics, Liquid Biopsy, NGS, Clinical Data, Laboratory Technology, Bioanalytical Testing, Tumor Biomarkers
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Jin Li, Senior Director, Scientific Affairs, ICON
Jason Gottwals, Genomic Enablement Manager - AMR, Illumina
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-06-17
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|